SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Oh JK, Shin HR, Gong G, Sohn JH, Khang SK. Diagnostic accuracy of conventional Pap test, liquid-based cytology and human papillomavirus DNA testing in cervical cancer screening in Korea: a meta-analysis. Korean J Epidemiol 2008; 30: 17887.
  • 2
    Abe N, Watanabe T, Izumisato Y et al. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. J Gastroenterol 2003; 38: 11449.
  • 3
    Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 827.
  • 4
    Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 66976.
  • 5
    Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30: 47789.
  • 6
    Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 5268.
  • 7
    Seok SH, Kim JM, Bae JM et al. Prognosis of gastrointestinal stromal tumors arising in the stomach and small intestine: a retrospective study of 126 Cases from a single institution. Korean J Pathol 2008; 42: 33543.
  • 8
    Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 45965.
  • 9
    Carrillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997; 28: 1605.
  • 10
    Filiz G, Yalcinkaya O, Gürel S, Yerci O, Memik F. The relationship between MIB-1 proliferative activity and mitotic index in gastrointestinal stromal tumors. Hepatogastroenterology 2007; 54: 43841.
  • 11
    Toquet C, Le Néel JC, Guillou L et al. Elevated (> or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases. Dig Dis Sci 2002; 47: 224753.
  • 12
    Yamaguchi U, Hasegawa T, Sakurai S et al. Interobserver variability in histologic recognition, interpretation of KIT immunostaining, and determining MIB-1 labeling indices in gastrointestinal stromal tumors and other spindle cell tumors of the gastrointestinal tract. Appl Immunohistochem Mol Morphol 2006; 14: 4651.
  • 13
    Bossard C, Jarry A, Colombeix C et al. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol 2006; 59: 70610.
  • 14
    Casper DJ, Ross KI, Messina JL et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol 2010; 32: 6504.
  • 15
    Colman H, Giannini C, Huang L et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 2006; 30: 65764.
  • 16
    Fukushima S, Terasaki M, Sakata K et al. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol 2009; 26: 517.
  • 17
    Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008; 30: 11722.
  • 18
    Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 2006; 30: 839.
  • 19
    Goto H, Tomono Y, Ajiro K et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 1999; 274: 255439.
  • 20
    Juan G, Traganos F, James WM et al. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 1998; 32: 717.
  • 21
    Cunningham RE, Abbondanzo SL, Chu WS, Emory TS, Sobin LH, O'Leary TJ. Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol 2001; 9: 1923.
  • 22
    Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78: 16336.
  • 23
    Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 5360.
  • 24
    O'Leary T, Ernst S, Przygodzki R, Emory T, Sobin L. Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1999; 79: 14617.
  • 25
    Wong NA, Young R, Malcomson RD et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003; 43: 11826.
  • 26
    Molenaar WM, Plaat BE, Berends ER, te Meerman GJ. Observer reliability in assessment of mitotic activity and MIB-1-determined proliferation rate in pediatric sarcomas. Ann Diagn Pathol 2000; 4: 22835.
  • 27
    Angi M, Damato B, Kalirai H, Dodson A, Taktak A, Coupland SE. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol 2011; 89: e15560.
  • 28
    Kapur P, Rakheja D, Balani JP, Roy LC, Amirkhan RH, Hoang MP. Phosphorylated histone H3, Ki-67, p21, fatty acid synthase, and cleaved caspase-3 expression in benign and atypical granular cell tumors. Arch Pathol Lab Med 2007; 131: 5764.
  • 29
    Ladstein RG, Bachmann IM, Straume O, Akslen LA. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 2010; 10: 140.
  • 30
    Liu X, Chen N, Wang X et al. Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules. J Neuropathol Exp Neurol 2006; 65: 90513.
  • 31
    Scott IS, Heath TM, Morris LS et al. A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer 2004; 90: 158390.
  • 32
    Yin W, Chen N, Zhang Y et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 2006; 19: 148797.
  • 33
    Hirano K, Shishido-Hara Y, Kitazawa A et al. Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): a potential marker for tumor proliferation. Pathol Res Pract 2008; 204: 799807.
  • 34
    Yasui H, Konishi E, Urasaki K, Yasukawa S, Yanagisawa A. Intratumoral heterogeneity of MIB-1 labelling index in gastric gastrointestinal stromal tumor (GIST). Gastric Cancer 2006; 9: 2238.
  • 35
    Veras E, Malpica A, Deavers MT, Silva EG. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol 2009; 28: 31621.